Skip to main content
Henan Taloph Pharmaceutical Stock Co.,Ltd logo

Henan Taloph Pharmaceutical Stock Co.,Ltd — Investor Relations & Filings

Ticker · 600222 ISIN · CNE0000010L8 LEI · 300300DV3SDIA91T7616 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,956 across all filing types
Latest filing 2026-05-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600222

About Henan Taloph Pharmaceutical Stock Co.,Ltd

http://www.taloph.com/

Henan Taloph Pharmaceutical Stock Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company’s portfolio primarily focuses on Traditional Chinese Medicine (TCM) and modern chemical pharmaceuticals. Key product categories include oral liquids, injections, tablets, and capsules, with a significant emphasis on treatments for respiratory, cardiovascular, and anti-infective conditions. One of its flagship products is the Shuanghuanglian Oral Liquid, widely utilized for its antiviral and antibacterial properties. The company operates integrated manufacturing facilities and maintains a robust research and development infrastructure to support product innovation and quality control. Its operations encompass the entire value chain from raw material sourcing to the marketing of finished dosage forms, serving healthcare markets through a comprehensive supply network.

Recent filings

Filing Released Lang Actions
太龙药业关于为下属全资及控股子公司融资提供担保的公告
Capital/Financing Update Classification · 85% confidence The document is a formal regulatory announcement (“公告”) by a listed company (600222) detailing guarantees provided for subsidiaries’ bank financing (amounts, counterparties, terms, board approvals, risk disclosures). This is not a financial statement (10-K/IR), nor an audit, management change, share issue, or dividend notice. It directly relates to the company’s financing activities (providing guarantees for loans), fitting the definition of a Capital/Financing Update (CAP).
2026-05-28 Chinese
太龙药业关于注销回购股份、减少注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 90% confidence The document is an official corporate announcement by Henan Tailong Pharmaceutical Co. regarding the cancellation of previously repurchased shares and the consequent reduction of registered capital, along with creditor notification procedures. This constitutes a capital structure change rather than a financial report, management change, or dividend notice. It best fits ‘Share Issue/Capital Change’ (SHA), which covers announcements of capital changes such as share cancellations and capital reductions.
2026-05-21 Chinese
河南仟问律师事务所关于河南太龙药业股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 78% confidence The document is a lawyer’s legal opinion letter regarding the convening, procedures, agenda, and voting results of the 2025 annual general meeting of shareholders. It is not the annual report itself, an earnings release, proxy solicitation materials, or any other narrowly defined filing type; instead, it serves as a legal attestation and compliance opinion. This falls under the catch-all Regulatory Filings category (RNS).
2026-05-21 Chinese
太龙药业关于召开2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 20% confidence The document is a formal announcement of the company’s upcoming 2026 Q1 performance explanation meeting (业绩说明会). It does not contain any financial statements or results itself, nor is it the actual Q1 report—which was already published on April 30—and it is not a presentation or transcript. It is an event notice/regulatory announcement that doesn’t fit any specific filing category, so per the fallback rule it should be classified as a general Regulatory Filing (RNS).
2026-05-12 Chinese
太龙药业2025年年度股东会会议资料
AGM Information Classification · 96% confidence The document is the full set of materials for the 2025 Annual General Meeting of 河南太龙药业股份有限公司, including meeting instructions, agenda, board work report, annual report summary, profit distribution proposal, and other proposals for shareholder approval. This corresponds exactly to AGM Information (materials shared during the AGM).
2026-05-12 Chinese
太龙药业2025年度内部控制审计报告
Audit Report / Information Classification · 98% confidence The document is a standalone internal control audit report issued by an independent accounting firm (大信会计师事务所) for 河南太龙药业股份有限公司, detailing the audit scope, responsibilities, and opinion on the effectiveness of financial reporting internal controls. It is not an annual report or merely an announcement of a report but a full audit report. According to the filing definitions, it fits the Audit Report / Information category (Code: AR). FY 2025
2026-04-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.